{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:57:50Z","timestamp":1793761070009,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.annonc.2023.05.005","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T11:38:45Z","timestamp":1684496325000},"page":"681-692","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":381,"title":["Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial"],"prefix":"10.1016","volume":"34","author":[{"given":"I.","family":"Ray-Coquard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cropet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"M\u00e4enp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Selle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Guerra Alia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lefeuvre-Plesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Buderath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Mosconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Burges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Medioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"El-Balat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-W.","family":"Park-Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dubot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Denschlag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.annonc.2023.05.005_bib1","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.annonc.2021.07.004","article-title":"Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines","volume":"32","author":"Colombo","year":"2021","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2023.05.005_bib2","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2023.05.005_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2023.05.005_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdx011","article-title":"Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions","volume":"28","author":"Karam","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2023.05.005_bib5","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2023.05.005_bib6","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.annonc.2023.05.005_bib7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.05.005_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-022-01732-7","article-title":"Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era","volume":"127","author":"You","year":"2022","journal-title":"Br J Cancer"},{"issue":"25","key":"10.1016\/j.annonc.2023.05.005_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.05.005_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejca.2022.07.022","article-title":"Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: main analysis of second progression-free survival in\u00a0the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"174","author":"Gonzalez-Martin","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2023.05.005_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2023.05.005_bib15","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/IGC.0000000000000478","article-title":"European Network of Gynaecological Oncological Trial Groups\u2019 requirements for trials between academic groups and industry partners--first update 2015","volume":"25","author":"du Bois","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2023.05.005_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/IGC.0b013e3181d3caa8","article-title":"European Network of Gynaecological Oncological Trial Groups\u2019 requirements for trials between academic groups and pharmaceutical companies","volume":"20","author":"Vergote","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2023.05.005_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2023.05.005_bib18","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2023.05.005_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejca.2021.08.023","article-title":"Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1\/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer","volume":"157","author":"Vergote","year":"2021","journal-title":"Eur J Cancer"},{"issue":"25","key":"10.1016\/j.annonc.2023.05.005_bib20","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.annonc.2023.05.005_bib21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2023.05.005_bib22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/ijgc-2021-002933","volume":"31","author":"Monk","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"23","key":"10.1016\/j.annonc.2023.05.005_bib23","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/djp369","article-title":"Detecting an overall survival benefit that is derived from progression-free survival","volume":"101","author":"Broglio","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.annonc.2023.05.005_bib24","doi-asserted-by":"crossref","first-page":"djv133","DOI":"10.1093\/jnci\/djv133","article-title":"Detecting overall survival benefit derived from survival postprogression rather than progression-free survival","volume":"107","author":"Morita","year":"2015","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.annonc.2023.05.005_bib25","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(22)00139-5","article-title":"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup","volume":"23","author":"Vergote","year":"2022","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.annonc.2023.05.005_bib26","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1200\/JCO.22.01003","article-title":"A\u00a0randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA\u2013MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2023.05.005_bib27","first-page":"439","article-title":"Late relapse of epithelial ovarian cancer: a single institution experience","volume":"26","author":"Bamias","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2023.05.005_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2023.05.005_bib29","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1200\/JCO.2022.40.16_suppl.5571","article-title":"Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"40","author":"Labidi-Galy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2023.05.005_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"10.1016\/j.annonc.2023.05.005_bib31","first-page":"A208","article-title":"201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative","volume":"31","author":"Pujade-Lauraine","year":"2021","journal-title":"Int J Gynecol Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423006865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423006865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T01:34:52Z","timestamp":1707528892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423006865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0923753423006865"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}